Detectives often find important clues by digging through rubbish. That approach paid off tremendously for systems biologist ...

A collaborative effort by the Formosa-Jordan lab from the Max Planck Institute for Plant Breeding Research in Cologne, ...

An investigation into cellular components in bacteria has unexpectedly uncovered a feature with relevance across many life ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

While some Syrians erupted in jubilant celebrations to mark a year since Assad fled, others refused to take part, and some ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced the ...

Interactive images make more sense in NotebookLM than in Gemini because it's a tool built specifically for learning, and not ...

The Geminid meteor shower will hit its peak the night of Saturday, Dec. 13, and continue into the morning hours of Sunday, ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients ...

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a ...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...

"Epcoritamab and R 2 is a novel chemotherapy-free fixed-duration therapy that is suitable for outpatient administration and, we believe, sets a new benchmark as a standard of care for second-line [or ...